$CLMT

Calumet (CLMT) Stock Falls As Cash Flow Strength Meets Equity Risk

Calumet (CLMT) shares fell 5.7% to $39.48 after Q2 2026 results. The company reported revenue of $1,445.1m, a net loss of $95.9m, and adjusted EBITDA of $175m, generating over $90m in cash from operations while continuing debt paydown. The article cites leverage below 4x and equity risk from negative equity.

Original reporting
Published Aug 9, 2026, 4:48 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 9, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Calumet (CLMT) Stock Falls As Cash Flow Strength Meets Equity Risk — source image
Decision brief

The 30-second read

$CLMTNeutralMed
01

Why it matters

Traders are reacting to the earnings-driven price move, while the longer-term debate centers on whether cash flow can sustainably reduce equity risk and leverage toward management’s stated path.

02

Market read

The key tradable tension is cash strength versus persistent losses and balance-sheet fragility, which can keep the stock sensitive to execution and policy/credit developments.

03

What to watch

The article cites foregone MaxSAF-150 margin and downtime; if those normalize, the renewables engine could scale faster than the bear case assumes, changing the free-cash-flow outlook.

Relevance 6/10Novelty 6/10Timing: post-earnings, pre-market positioning after the Q2 print and same-day -5.7% close

Background

Simply Wall St frames Calumet’s Q2 as a cash-generation and debt-reduction inflection, but notes equity deficits and working-capital absorption remain unresolved.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Calumet shares fell 5.7% after Q2 results, with adjusted EBITDA of $175m and cash from operations above $90m, alongside a still-large net loss.

Expected impact

Near-term downside risk persists while net loss, working-capital cash absorption, and policy/credit volatility are not fully resolved; upside depends on continued leverage reduction toward management’s sub-3x target.

Evidence & confidence

The article provides concrete Q2 cash and leverage signals, yet also highlights ongoing net loss and working-capital drag, which can offset the positive cash engine narrative and drive volatility.

Market effects

Renewables and specialty fuels operators may see investor focus shift toward cash conversion and leverage trajectory rather than headline earnings.

No specific regional spillover is described beyond the company-specific balance-sheet narrative.

Limited global relevance; the story is primarily company-specific within specialty fuels/renewables.

Counterpoint

The market may be over-penalizing the net loss line item while underweighting the $90m+ operating cash and debt retirement progress that could improve equity risk over subsequent quarters.

Key entities

  • Calumet

    CLMT, reported Q2 2026 results with $175m adjusted EBITDA, $90m+ operating cash, and a still-material net loss, leading to a -5.7% stock drop.

Related articles

$CLMTMed

S&P upgrades Calumet rating to B- on stronger earnings

S&P Global Ratings upgraded Calumet Inc. to 'B-' from 'CCC+' due to stronger earnings in H1 2026 and improved credit metrics. The company's earnings grew on high margins for specialty oils and renewable fuels. S&P expects adjusted debt to EBITDA of 6x-7x in the next 12 months. Calumet redeemed $100M in senior unsecured notes in July 2026 and plans to expand sustainable aviation fuel production.

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.